Chinese regulators crack down on counterfeiters; BASi reports 14% revenue drop in Q3;

> Chinese regulators are sick of counterfeit drugs and devices getting into the company's market, so the government is publishing a blacklist of manufacturers and suppliers who have run afoul of Chinese law. Item

> BASi ($BASi) saw its revenue drop 14% to $7.2 million in the third quarter, but the company is optimistic about its future growth. News

> WuXi PharmaTech's Suzhou facility received GLP certification from China's State Food and Drug Administration, allowing the company to perform non-clinical lab studies there. Article

> IMS Health has purchased TTC, an outfit that specializes in calculating cost and negotiating prices for clinical trials. The company didn't disclose an acquisition price. More

> The FDA has updated its guidance on suicide risk in clinical trials, responding to increasing reports of certain populations taking antidepressants and antiepileptics. Story

> DaVita is opening a Colorado Phase I facility to focus on kidney research, targeting drugmakers seeking renal trials. Report

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.